Veracyte, Inc. Amends Prior 8-K Filing
Ticker: VCYT · Form: 8-K/A · Filed: Apr 17, 2024 · CIK: 1384101
| Field | Detail |
|---|---|
| Company | Veracyte, Inc. (VCYT) |
| Form Type | 8-K/A |
| Filed Date | Apr 17, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, financial-statements, exhibits
TL;DR
Veracyte filed an amendment to its February 5th report, updating financial statements and exhibits.
AI Summary
Veracyte, Inc. filed an 8-K/A on April 17, 2024, to amend a previous filing from February 5, 2024. This amendment pertains to financial statements and exhibits, though specific details of the changes are not provided in this excerpt. The company, previously known as Calderome Inc., is incorporated in Delaware and headquartered in South San Francisco, California.
Why It Matters
This filing indicates an update or correction to previously submitted financial information, which could be important for investors assessing the company's financial health.
Risk Assessment
Risk Level: low — This is an amendment to a previous filing, not a new material event, and the excerpt lacks specific details of the changes.
Key Players & Entities
- VERACYTE, INC. (company) — Registrant
- CALDEROME INC (company) — Former company name
- February 5, 2024 (date) — Date of earliest event reported
- April 17, 2024 (date) — Date of report and amendment
- South San Francisco, California (location) — Principal executive offices
FAQ
What is the purpose of this 8-K/A filing?
The purpose of this 8-K/A filing is to amend a previous Form 8-K filed on February 5, 2024, specifically concerning financial statements and exhibits.
When was the original event reported that this filing amends?
The original event was reported on February 5, 2024.
What is Veracyte, Inc.'s principal executive office address?
Veracyte, Inc.'s principal executive office is located at 6000 Shoreline Court, Suite 300, South San Francisco, California 94080.
What was Veracyte, Inc. formerly known as?
Veracyte, Inc. was formerly known as CALDEROME INC.
What is the filing date of this amended report?
This amended report (8-K/A) was filed on April 17, 2024.
Filing Stats: 826 words · 3 min read · ~3 pages · Grade level 13.5 · Accepted 2024-04-17 16:34:49
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share VCYT The Nasdaq Stock Market
Filing Documents
- vcyt-20240205.htm (8-K/A) — 33KB
- ex231c2ifinancialsconsent.htm (EX-23.1) — 5KB
- ex991c2igenomics2023.htm (EX-99.1) — 390KB
- ex9922023proformastatements.htm (EX-99.2) — 319KB
- eyheader.gif (GRAPHIC) — 7KB
- 0001384101-24-000051.txt ( ) — 956KB
- vcyt-20240205.xsd (EX-101.SCH) — 2KB
- vcyt-20240205_lab.xml (EX-101.LAB) — 23KB
- vcyt-20240205_pre.xml (EX-101.PRE) — 13KB
- vcyt-20240205_htm.xml (XML) — 5KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (a) Financial Statements of Business Acquired Included in this Current Report on Form 8-K/A are the audited financial statements of C2i Genomics as of and for the year ended December 31, 2023, which are filed as Exhibit 99.1 and are incorporated herein by reference. (b) Pro Forma Financial Information Veracyte is also filing the unaudited pro forma condensed combined financial statements of Veracyte giving effect to the Acquisition as of and for the year ended December 31, 2023, which is filed as Exhibit 99.2 and is incorporated herein by reference. (d) Exhibits Exhibit No. Description 23.1 Consent of Kost Forer Gabbay & Kasierer, a member of EY Global , Indepe ndent Auditors of C2i Genomics . 99.1 Audited financial statements of C2i Genomics as of and for the year ended December 31, 2023. 99.2 Unaudited pro forma condensed combined financial statements of Veracyte as of and for the year ended December 31, 2023. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: April 17, 2024 VERACYTE, INC. By: /s/ Rebecca Chambers Name: Rebecca Chambers Title: Chief Financial Officer Principal Financial Officer